VivoSeq
Other

Fear

0

Pipeline Programs

5

Active Trials

2

Companies Involved

Fear is an early-stage landscape with 0 programs across 2 companies. The most active players are Sibel Akgül Kartal, Universite de Picardie Jules Verne.

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

27/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

11

clinical trials

Not yet recruiting3 · 27%
Completed3 · 27%
Recruiting2 · 18%
Withdrawn2 · 18%
Terminated1 · 9%

Trial Activity

11 trials

Inflammatory Challenge and Fear
Recruiting·UUniversity of California, San Francisco·Phase 1·NCT06630884·288 enrolled
Cannabidiol Effects on Fear Extinction in Social Phobia
Not yet recruiting·HHartford Hospital·Phase 1·NCT06123702·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)